Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

SLC6A14, an amino acid transporter, modifies the primary CF defect in fluid secretion.

Ahmadi S, Xia S, Wu YS, Di Paola M, Kissoon R, Luk C, Lin F, Du K, Rommens J, Bear CE.

Elife. 2018 Jul 13;7. pii: e37963. doi: 10.7554/eLife.37963.

2.

Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.

Chin S, Hung M, Won A, Wu YS, Ahmadi S, Yang D, Elmallah S, Toutah K, Hamilton CM, Young RN, Viirre RD, Yip CM, Bear CE.

Mol Pharmacol. 2018 Aug;94(2):917-925. doi: 10.1124/mol.118.112177. Epub 2018 Jun 14.

PMID:
29903751
3.

Inhalational Anesthetics Induce Neuronal Protein Aggregation and Affect ER Trafficking.

Coghlan M, Richards E, Shaik S, Rossi P, Vanama RB, Ahmadi S, Petroz C, Crawford M, Maynes JT.

Sci Rep. 2018 Mar 27;8(1):5275. doi: 10.1038/s41598-018-23335-0.

4.

SLC6A14 Is a Genetic Modifier of Cystic Fibrosis That Regulates Pseudomonas aeruginosa Attachment to Human Bronchial Epithelial Cells.

Di Paola M, Park AJ, Ahmadi S, Roach EJ, Wu YS, Struder-Kypke M, Lam JS, Bear CE, Khursigara CM.

MBio. 2017 Dec 19;8(6). pii: e02073-17. doi: 10.1128/mBio.02073-17.

5.

Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue.

Molinski SV, Ahmadi S, Ip W, Ouyang H, Villella A, Miller JP, Lee PS, Kulleperuma K, Du K, Di Paola M, Eckford PD, Laselva O, Huan LJ, Wellhauser L, Li E, Ray PN, Pomès R, Moraes TJ, Gonska T, Ratjen F, Bear CE.

EMBO Mol Med. 2017 Sep;9(9):1224-1243. doi: 10.15252/emmm.201607137.

6.

Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia.

Ahmadi S, Bozoky Z, Di Paola M, Xia S, Li C, Wong AP, Wellhauser L, Molinski SV, Ip W, Ouyang H, Avolio J, Forman-Kay JD, Ratjen F, Hirota JA, Rommens J, Rossant J, Gonska T, Moraes TJ, Bear CE.

NPJ Genom Med. 2017 Apr 14;2:12. doi: 10.1038/s41525-017-0015-6.

7.

Biophysical Approaches Facilitate Computational Drug Discovery for ATP-Binding Cassette Proteins.

Molinski SV, Bozóky Z, Iram SH, Ahmadi S.

Int J Med Chem. 2017;2017:1529402. doi: 10.1155/2017/1529402. Epub 2017 Mar 19. Review.

8.

Synergy of cAMP and calcium signaling pathways in CFTR regulation.

Bozoky Z, Ahmadi S, Milman T, Kim TH, Du K, Di Paola M, Pasyk S, Pekhletski R, Keller JP, Bear CE, Forman-Kay JD.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2086-E2095. doi: 10.1073/pnas.1613546114. Epub 2017 Feb 27.

9.

Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening.

Molinski SV, Ahmadi S, Hung M, Bear CE.

J Biomol Screen. 2015 Dec;20(10):1204-17. doi: 10.1177/1087057115605834. Epub 2015 Sep 18.

PMID:
26385858
10.

Directed differentiation of cholangiocytes from human pluripotent stem cells.

Ogawa M, Ogawa S, Bear CE, Ahmadi S, Chin S, Li B, Grompe M, Keller G, Kamath BM, Ghanekar A.

Nat Biotechnol. 2015 Aug;33(8):853-61. doi: 10.1038/nbt.3294. Epub 2015 Jul 13.

PMID:
26167630
11.

Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity.

Malik FA, Meissner A, Semenkov I, Molinski S, Pasyk S, Ahmadi S, Bui HH, Bear CE, Lidington D, Bolz SS.

PLoS One. 2015 Jun 16;10(6):e0130313. doi: 10.1371/journal.pone.0130313. eCollection 2015.

12.

The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.

Pasyk S, Molinski S, Ahmadi S, Ramjeesingh M, Huan LJ, Chin S, Du K, Yeger H, Taylor P, Moran MF, Bear CE.

Proteomics. 2015 Jan;15(2-3):447-61. doi: 10.1002/pmic.201400218. Epub 2014 Dec 17.

PMID:
25330774
13.

VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.

Eckford PD, Ramjeesingh M, Molinski S, Pasyk S, Dekkers JF, Li C, Ahmadi S, Ip W, Chung TE, Du K, Yeger H, Beekman J, Gonska T, Bear CE.

Chem Biol. 2014 May 22;21(5):666-78. doi: 10.1016/j.chembiol.2014.02.021. Epub 2014 Apr 10.

14.

Conformational defects underlie proteasomal degradation of Dent's disease-causing mutants of ClC-5.

D'Antonio C, Molinski S, Ahmadi S, Huan LJ, Wellhauser L, Bear CE.

Biochem J. 2013 Jun 15;452(3):391-400. doi: 10.1042/BJ20121848.

PMID:
23566014
15.

Functional Rescue of F508del-CFTR Using Small Molecule Correctors.

Molinski S, Eckford PD, Pasyk S, Ahmadi S, Chin S, Bear CE.

Front Pharmacol. 2012 Sep 26;3:160. doi: 10.3389/fphar.2012.00160. eCollection 2012.

Supplemental Content

Loading ...
Support Center